Search results
Found 30036 matches for
Better diagnosis and treatment of autoimmune diseases moves a step closer
5 January 2023
A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.
New drug offers hope for people with hand osteoarthritis
22 December 2022
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.
Professor Michael Dustin appointed new Chair in Molecular Immunology
6 December 2022
A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.
Empowering data science for single-cell analysis in Zimbabwe
5 December 2022
An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.
T-cell coreceptors are well endowed—with kinases!
2 December 2022
The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.
Two prestigious Hunterian Professorships awarded to NDORMS researchers
1 December 2022
Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England
Dr Alex Clarke wins Emerging Leaders Prize for lupus research
30 November 2022
Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.
Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
15 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
Patients like me
1 November 2022
What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.
Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination
28 October 2022
Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.
NDORMS contributes to new UK research to tackle monkeypox outbreak
25 October 2022
The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.
World Osteoporosis Day 2022
20 October 2022
A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.
Mathematician boosts data science research at the Kennedy Institute
19 October 2022
Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.
NIHR funding for musculoskeletal and inflammatory disease research
17 October 2022
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.
IMPROVE Study opens to recruitment
12 October 2022
OCTRU and the Experimental Medicine and Rheumatology trial group are delighted to announce that their latest study IMPROVE is now open and recruiting. The IMPROVE study is investigating if the immune response to COVID-19 vaccination can be improved in those with Chronic Lymphocytic Leukaemia (CLL) by pausing BTKi treatment for 3 weeks around the time of vaccination. The study is led by Dr Helen Parry at the University of Birmingham and funded by the NIHR and will recruit around 120 patients from 8 NHS Trusts in the UK. To coincide with the autumn COVID-19 vaccination programme all those involved in the study set have been working at great pace to reach this critical milestone and we look forward to supporting sites during the busy recruitment period.
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.
Three NIHR HTA grants awarded to Professor Tim Theologis
4 October 2022
Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.